WHEAT BRAN FIBER EFFECT ON ADENOMATOUS POLYP RECURRENCE

麦麸纤维对腺瘤性息肉复发的影响

基本信息

  • 批准号:
    6236786
  • 负责人:
  • 金额:
    $ 36.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-03-01 至 1998-02-28
  • 项目状态:
    已结题

项目摘要

Colorectal cancer continues as the second leading cause of cancer death in the United States with 53,000 deaths in 1993. There is continuing controversy concerning the potential role of dietary fiber in the prevention of colon cancer. The results of animal studies, human epidemiologic studies, and mechanisms of action evaluations strongly suggest an inverse relationship between wheat bran fiber intake and colon adenoma and cancer incidence. Furthermore, high intakes of wheat bran fiber in both experimental carcinogenesis animal models and human metabolic epidemiology studies has been associated with significant reductions in fecal secondary bile acids, especially deoxycholic acid which is a well documented colon tumor promoting agent. Results of two relatively small, randomized Phase III intervention studies have been published. De Cosse et al. found that fiber supplementation in excess of 11 gm/day reduced the incidence of polyp recurrence in their study of 58 patients with familial adenomatous polyposis. A preliminary analysis of a study by Macrae and MacLennan in 400 patients with resected adenomatous polyps suggested that wheat bran fiber supplementation is associated with a significant reduction in recurrent adenoma size and degree of dysplasia. In our previous study of wheat bran fiber and calcium supplementation in 100 patients with resected colonic polyps we found high dose wheat bran fiber (13.5 gm/d) significantly reduced fecal total, primary, and secondary (including deoxycholic acid) bile acid concentrations and excretion rates at 9 months of supplementation as compared to baseline and 3 month levels. Our current, double-blind, placebo controlled Phase III cancer control study has been designed to measure the effects of wheat bran fiber supplementation (13.5 gm/d vs 2.0 gm/d X 3 years) on adenoma recurrence (at the year one and three year colonoscopies), epithelial cell proliferation (as measured by proliferating cell nuclear antigen or PCNA Labeling Index), fecal and plasma bile acid concentrations, and protein kinase C isotype expression and enzyme activity. To date more than 1550 patients with a history of a resected adenomatous polyp (within three months of diagnosis and consent) have been accrued and 1250 patients have been randomized to one of the two arms. Patient accrual is ongoing until Fall 1994 to achieve 950 fully evaluable patients who will undergo the year three colonoscopy while on-study. Rectal mucosal biopsy samples have been obtained from a 25% subset of randomized patients at baseline, and will be repeated at one, two, and three years of follow-up for PCNA LI and PKC isotype expression and enzyme activity. The wheat bran fiber supplements have been well tolerated with excellent patient compliance although non-cereal eaters have proven difficult study participants. This Project Protocol outlines the background, significance, aims, procedures, and progress of our Phase III wheat bran fiber trial in patients with resected adenomatous polyps.
结直肠癌仍然是癌症死亡的第二大原因

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Samuel Alberts其他文献

David Samuel Alberts的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Samuel Alberts', 18)}}的其他基金

Cancer Prevention and Control Health Disparities Training Program
癌症预防与控制健康差异培训计划
  • 批准号:
    10004567
  • 财政年份:
    2016
  • 资助金额:
    $ 36.57万
  • 项目类别:
Cancer Prevention and Control Health Disparities Training Program
癌症预防和控制健康差异培训计划
  • 批准号:
    9352784
  • 财政年份:
    2016
  • 资助金额:
    $ 36.57万
  • 项目类别:
Cancer Prevention and Control Health Disparities Training Program
癌症预防与控制健康差异培训计划
  • 批准号:
    9208596
  • 财政年份:
    2016
  • 资助金额:
    $ 36.57万
  • 项目类别:
Development
发展
  • 批准号:
    7944505
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
  • 批准号:
    8302390
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
  • 批准号:
    8533555
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
  • 批准号:
    8100422
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:
Senior Leaders
高层领导
  • 批准号:
    7944488
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
  • 批准号:
    8541610
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:
The Partnership for Native American Cancer Prevention (2 of 2)
美洲原住民癌症预防伙伴关系(2 of 2)
  • 批准号:
    8691078
  • 财政年份:
    2009
  • 资助金额:
    $ 36.57万
  • 项目类别:

相似国自然基金

基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
  • 批准号:
    61602201
  • 批准年份:
    2016
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
  • 批准号:
    81170309
  • 批准年份:
    2011
  • 资助金额:
    50.0 万元
  • 项目类别:
    面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
  • 批准号:
    30672394
  • 批准年份:
    2006
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

Comprehensive genetic analysis-based liquid biopsy for establishment of the novel tumor biomarker in dog
基于综合遗传分析的液体活检建立狗的新型肿瘤生物标志物
  • 批准号:
    21K05952
  • 财政年份:
    2021
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Towards a Virtual Biopsy: An improved multimodal imaging biomarker to guide treatment decisions in neuro-oncology by combining advanced tissue microstructure imaging with deep learning
走向虚拟活检:一种改进的多模态成像生物标志物,通过将先进的组织微观结构成像与深度学习相结合来指导神经肿瘤学的治疗决策
  • 批准号:
    10325327
  • 财政年份:
    2021
  • 资助金额:
    $ 36.57万
  • 项目类别:
Study for novel biomarker in liquid biopsy on on carcinogenic pathways induced by driver mutations
液体活检中驱动突变诱发致癌途径的新型生物标志物研究
  • 批准号:
    20K07671
  • 财政年份:
    2020
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of liquid biopsy biomarker for precision neoadjuvant treatment for pancreatic cancer
胰腺癌精准新辅助治疗液体活检生物标志物的开发
  • 批准号:
    20K22861
  • 财政年份:
    2020
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Novel Multiplex Biomarker Discovery Methods To Predict Breast Cancer Risk After A Benign Biopsy
良性活检后预测乳腺癌风险的新型多重生物标志物发现方法
  • 批准号:
    10021604
  • 财政年份:
    2019
  • 资助金额:
    $ 36.57万
  • 项目类别:
Biomarker screening of urothelial carcinoma using liquid biopsy
使用液体活检进行尿路上皮癌生物标志物筛查
  • 批准号:
    19K18575
  • 财政年份:
    2019
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Clinical significance of liquid biopsy using a novel biomarker for sarcoma
使用新型肉瘤生物标志物进行液体活检的临床意义
  • 批准号:
    19K09650
  • 财政年份:
    2019
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The search of biomarker for the liquid-biopsy to diagnose the cellular infiltration in the kidney injury
液体活检诊断肾损伤细胞浸润生物标志物的探索
  • 批准号:
    18K05996
  • 财政年份:
    2018
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of kidney cancer biomarker for therapeutic efficacy by using imaging and liquid biopsy
利用成像和液体活检开发肾癌生物标志物以提高治疗效果
  • 批准号:
    18K16719
  • 财政年份:
    2018
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
New biomarker for recurrence of HCC by using liquid biopsy
通过液体活检发现 HCC 复发的新生物标志物
  • 批准号:
    17K10678
  • 财政年份:
    2017
  • 资助金额:
    $ 36.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了